Clinical Trials

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04557007 2026-01-29

Oncomabs

Terminated

80 enrolled

NSCLC

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT06607393 2024-09-23

CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]

851 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06585189 2024-09-05

CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]

304 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT04291755 2024-04-05

Development and Analysis of a Stool Bank for Cancer Patients

Recruiting

100 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05418660 2023-09-18

I-STOP

300 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05908799 2023-09-13

Emulation of the KEYNOTE-189 Trial Using Electronic Health Records

1,854 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

DermatologicGenitourinaryThoracic

1,800 enrolled

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT05023837 2022-01-25

Esporta

40 enrolled

Uncommon Pathological Types of Lung Cancer

NCT04465942 2021-08-23

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

300 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04860076 2021-04-26

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

400 enrolled

DermatologicThoracic

Lung Neoplasms, Melanoma

NCT03373955 2021-03-18

A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients

60 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04076228 2020-09-02

Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients

37 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03695835 2020-07-22

NIRPA

GastrointestinalGenitourinaryThoracic

27 enrolled

Adenocarcinoma, Urinary Bladder Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

4,724 enrolled